Portfolio company
Purespring Therapeutics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops gene therapies for patients with chronic renal diseases to preserve kidney function and treat conditions like IgA nephropathy.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Purespring
Purespring develops gene therapies targeting podocyte cells to treat chronic kidney diseases for patients with conditions such as IgA nephropathy and Alport syndrome.
Nephrogen
This biotechnology company develops artificial intelligence-driven gene therapies to treat kidney and pancreatic diseases for patients with genetic conditions.
Trestle Biotherapeutics
This company develops implantable bioengineered kidney tissues to restore renal function for patients suffering from end-stage renal disease.
Estuary Biotherapeutics
This biotechnology company develops targeted genetic medicines for patients with serious kidney conditions, specifically autosomal dominant polycystic kidney disease.
Chinook Therapeutics
This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.
Nionyx Bio
The company develops adeno-associated virus gene therapies for patients with genetic kidney diseases.
Helex
This biotechnology company develops gene editing therapeutics and lipid nanoparticle delivery platforms for patients suffering from genetic kidney diseases.
River Renal
This clinical-stage biotechnology company develops novel pharmaceutical therapies targeting orphan renal diseases for patients with unmet medical needs.